|
1
|
Verhoeven DT, Goldbohm RA, van Poppel G,
Verhagen H and van den Brandt PA: Epidemiological studies on
brassica vegetables and cancer risk. Cancer Epidemiol Biomarkers
Prev. 5:733–748. 1996.
|
|
2
|
Gullett NP, Ruhul Amin AR, Bayraktar S,
Pezzuto JM, Shin DM, Khuri FR, Aggarwal BB, Surh YJ and Kucuk O:
Cancer prevention with natural compounds. Semin Oncol. 37:258–281.
2010.
|
|
3
|
Cheung KL and Kong AN: Molecular targets
of dietary phenethyl isothiocyanate and sulforaphane for cancer
chemoprevention. AAPS J. 12:87–97. 2010.
|
|
4
|
Clarke JD, Dashwood RH and Ho E:
Multi-targeted prevention of cancer by sulforaphane. Cancer Lett.
269:291–304. 2008.
|
|
5
|
Mahéo K, Morel F, Langouet S, Kramer H, Le
Ferrec E, Ketterer B and Guillouzo A: Inhibition of cytochromes
P-450 and induction of glutathione S-transferases by sulforaphane
in primary human and rat hepatocytes. Cancer Res. 57:3649–3652.
1997.
|
|
6
|
Zhou C, Poulton EJ, Grun F, Bammler TK,
Blumberg B, Thummel KE and Eaton DL: The dietary isothiocyanate
sulforaphane is an antagonist of the human steroid and xenobiotic
nuclear receptor. Mol Pharmacol. 71:220–229. 2007.
|
|
7
|
Saracino MR and Lampe JW: Phytochemical
regulation of UDP-glucuronosyltransferases: implications for cancer
prevention. Nutr Cancer. 59:121–141. 2007.
|
|
8
|
Strassburg CP, Kalthoff S and Ehmer U:
Variability and function of family 1 uridine-5′-diphosphate
glucuronosyltransferases (UGT1A). Crit Rev Clin Lab Sci.
45:485–530. 2008.
|
|
9
|
Wang M, Sun DF, Wang S, Qing Y, Chen S, Wu
D, Lin YM, Luo JZ and Li YQ: Polymorphic expression of
UDP-glucuronosyltransferase UGTlA gene in human colorectal cancer.
PLoS One. 8:e570452013.
|
|
10
|
Shintani T and Klionsky DJ: Autophagy in
health and disease: a double-edged sword. Science. 306:990–995.
2004.
|
|
11
|
Mizushima N, Yoshimori T and Levine B:
Methods in mammalian autophagy research. Cell. 140:313–326.
2010.
|
|
12
|
Chen HY and White E: Role of autophagy in
cancer prevention. Cancer Prev Res. 4:973–983. 2011.
|
|
13
|
Herman-Antosiewicz A, Johnson DE and Singh
SV: Sulforaphane causes autophagy to inhibit release of cytochrome
C and apoptosis in human prostate cancer cells. Cancer Res.
66:5828–5835. 2006.
|
|
14
|
Nishikawa T, Tsuno NH, Okaji Y, Shuno Y,
Sasaki K, Hongo K, Sunami E, Kitayama J, Takahashi K and Nagawa H:
Inhibition of autophagy potentiates sulforaphane-induced apoptosis
in human colon cancer cells. Ann Surg Oncol. 17:592–602. 2010.
|
|
15
|
Kanematsu S, Uehara N, Miki H, Yoshizawa
K, Kawanaka A, Yuri T and Tsubura A: Autophagy inhibition enhances
sulforaphane-induced apoptosis in human breast cancer cells.
Anticancer Res. 30:3381–3390. 2010.
|
|
16
|
Svehliková V, Wang S, Jakubíková J,
Williamson G, Mithen R and Bao Y: Interactions between sulforaphane
and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells.
Carcinogenesis. 25:1629–1637. 2004.
|
|
17
|
Jakubíková J, Sedlák J, Mithen R and Bao
Y: Role of PI3K/Akt and MEK/ERK signaling pathways in
sulforaphane-and erucin-induced phase II enzymes and MRP2
transcription, G2/M arrest and cell death in Caco-2 cells. Biochem
Pharmacol. 9:1543–1552. 2005.
|
|
18
|
Gardner-Stephen D, Heydel JM, Goyal A, Lu
Y, Xie W, Lindblom T, Mackenzie P and Radominska-Pandya A: Human
PXR variants and their differential effects on the regulation of
human UDP-glucuronosyltransferase gene expression. Drug Metab
Dispos. 32:340–347. 2004.
|
|
19
|
Kuma A, Matsui M and Mizushima N: LC3, an
autophagosome marker, can be incorporated into protein aggregates
independent of autophagy: caution in the interpretation of LC3
localization. Autophagy. 3:323–328. 2007.
|
|
20
|
Tong KI, Kobayashi A, Katsuoka F and
Yamamoto M: Two-site substrate recognition model for the Keap1-Nrf2
system: a hinge and latch mechanism. Biol Chem. 387:1311–1320.
2006.
|
|
21
|
Wang M, Li YQ, Zhong N, Chen J, Xu XQ and
Yuan MB: Induction of uridine
5′-diphosphate-glucuronosyltransferase gene expression by
sulforaphane and its mechanism: experimental study in human colon
cancel cells. Zhonghua Yi Xue Za Zhi. 85:819–824. 2005.(in
Chinese).
|
|
22
|
Xie W, Yeuh MF, Radominska-Pandya A, Saini
SP, Negishi Y, Bottroff BS, Cabrera GY, Tukey RH and Evans RM:
Control of steroid, heme, and carcinogen metabolism by nuclear
pregnane X receptor and constitutive androstane receptor. Proc Natl
Acad Sci USA. 100:4150–4155. 2003.
|
|
23
|
Kliewer SA, Goodwin B and Willson TM: The
nuclear pregnane X receptor: a key regulator of xenobiotic
metabolism. Endocr Rev. 23:687–702. 2002.
|
|
24
|
Naumann P, Fortunato F, Zentgraf H,
Büchler MW, Herr I and Werner J: Autophagy and cell death signaling
following dietary sulforaphane act independently of each other and
require oxidative stress in pancreatic cancer. Int J Oncol.
39:101–109. 2011.
|
|
25
|
Li J, Hou N, Faried A, Tsutsumi S and
Kuwano H: Inhibition of autophagy augments 5-fluorouracil
chemotherapy in human colon cancer in vitro and in vivo model. Eur
J Cancer. 46:1900–1909. 2010.
|
|
26
|
Liu D, Yang Y, Liu Q and Wang J:
Inhibition of autophagy by 3-MA potentiates cisplatin-induced
apoptosis in esophageal squamous cell carcinoma cells. Med Oncol.
28:105–111. 2011.
|
|
27
|
Wang M, Chen S, Wang S, Sun D, Chen J, Li
Y, Han W, Yang X and Gao HQ: Effects of phytochemicals sulforaphane
on uridine diphosphate-glucuronosyltransferase expression as well
as cell-cycle arrest and apoptosis in human colon cancer Caco-2
cells. Chin J Physiol. 55:134–144. 2012.
|
|
28
|
Buckley DB and Klaassen CD: Induction of
mouse UDP-glucuronosyltransferase mRNA expression in liver and
intestine by activators of aryl-hydrocarbon receptor, constitutive
androstane receptor, pregnane X receptor, peroxisome
proliferator-activated receptor alpha, and nuclear factor erythroid
2-related factor 2. Drug Metab Dispos. 37:847–856. 2009.
|
|
29
|
Sugatani J, Yamakawa K, Tonda E, Nishitani
S, Yoshinari K, Degawa M, Abe I, Noguchi H and Miwa M: The
induction of human UDP-glucuronosyltransferase 1A1 mediated through
a distal enhancer module by flavonoids and xenobiotics. Biochem
Pharmacol. 67:989–1000. 2004.
|
|
30
|
Bozina N, Bradamante V and Lovrić M:
Genetic polymorphism of metabolic enzymes P450 (CYP) as a
susceptibility factor for drug response, toxicity, and cancer risk.
Arh Hig Rada Toksikol. 60:217–242. 2009.
|
|
31
|
Guengerich FP: Cytochrome P-450 3A4:
regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol.
39:1–17. 1999.
|
|
32
|
Kamdem LK, Meineke I, Gödtel-Armbrust U,
Brockmöller J and Wojnowski L: Dominant contribution of P450 3A4 to
the hepatic carcinogenic activation of aflatoxin B1. Chem Res
Toxicol. 19:577–586. 2006.
|
|
33
|
Gross-Steinmeyer K, Stapleton PL, Tracy
JH, Bammler TK, Strom SC and Eaton DL: Sulforaphane- and phenethyl
isothiocyanate-induced inhibition of aflatoxin B1-mediated
genotoxicity in human hepatocytes: role of GSTM1 genotype and
CYP3A4 gene expression. Toxicol Sci. 116:422–432. 2010.
|
